Coherus Oncology Proposes Stock Offering as Q4 Revenues Drop 75.8%
Coherus Oncology announced a proposed public offering of common stock with terms yet to be disclosed. For the quarter ended December 2025, the company is forecast to report a $0.31 per share loss, a 10.7% increase in loss, on revenues of $13.12 million, down 75.8% year-over-year.
1. Proposed Public Offering
Coherus Oncology filed a registration for a public offering of common stock, though the size, price range and timing have not been announced. The move signals a need to bolster liquidity amid a challenging operating environment and likely aims to fund ongoing clinical programs and working capital requirements.
2. Q4 2025 Financial Outlook
Analysts expect Coherus to report a loss of $0.31 per share for the quarter ended December 2025, a 10.7% wider loss compared to a year earlier. Revenue is projected to plunge 75.8% year-over-year to $13.12 million, reflecting diminished sales of its flagship biosimilar products.